Atlas Venture invests in Novexel
Client(s) Atlas Venture
Jones Day advised Atlas Venture in connection with its purchase of €50 million ($64.6 million) of Series B Convertible Preferred Stock in a private placement by Novexel SA, a pharmaceutical company focused on the discovery and development of novel antibiotics and anti-fungals.